Diagnostics Solutions Strategic Priorities
Roche is an IVD market leader in cardiovascular diseases
Highest benefit class and evidence level in major cardiac guidelines
Roche
Core Lab cardiovascular market share in 2019¹
Clinical practice guidelines⁹
34%
Roche
19%
17%
SIEMENS
Healthineers
Abbott
A Promise for Life
9%
QUIDEL
6%
①
DANAHER
16%
Others
Elecsys Troponin T Gen 5 STAT
Elecsys and
A
cobas e analyzers
IVD
"Redefining the gold standard of myocardial
infarction using Troponin T"
•
Diagnosis²,3
•
Risk prediction 2,3
cobas
.
Early invasive strategy²
"NT-proBNP: The gold standard biomarker
in heart failure"7
•
•
Diagnosis 5,6
Prognosis6
-
1 Source
Roche Diagnostics with BBC; 2 Roff M et al, Eur Heart J 2016; 37: 267; 3 Amsterdam EA et al., Circulation 2014;130:2354; 4 Ohman EM. Clin Chem 2017; 63: 429; 5 Ponikowski P et al., Eur Heart J 2016;
37:2129; 6 Yancy CW et al, Circulation. 2017;136:e137; 7 McKie PM et al, J Am Coll Cardiol 2016;68:2437; 8 American College of Cardiology / American Heart Association
56View entire presentation